Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lipopolysaccharide (LPS)
Lipopolysaccharide · 1 trial · 1 indication
Change from the baseline in CRP levels will be reported.
| Arm | Type | Description |
|---|---|---|
| Active Arm: Adalimumab + Lipopolysaccharide (LPS) Challenge | EXPERIMENTAL | Healthy participants will receive adalimumab subcutaneous (SC) injections via prefilled syringe or prefilled pen on Day 1, followed by the LPS intravenous (IV) injection challenge on Day 6. |
| Control Arm: LPS Challenge | EXPERIMENTAL | Participants will receive LPS IV injection on Day 6. No study interaction will be administered. |
| Name | Type | Description |
|---|---|---|
| Adalimumab | DRUG | Adalimumab will be administered subcutaneously. |
| Lipopolysaccharide (LPS) | DRUG | LPS will be administered intravenously. |
Inclusion Criteria: * A female participant must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of 5 months after adalimumab administration * A female participant must agree not to be pregnant or planning to become pregnant while e...
Lipopolysaccharide (LPS) is a small molecule being developed by Johnson & Johnson under the ticker JNJ. It is in Phase 1 clinical development. The therapeutic indication has not been disclosed. One Phase 1 trial of Lipopolysaccharide has been completed, enrolling 20 participants.
Lipopolysaccharide is being developed by Johnson & Johnson, which trades under the ticker JNJ. The company has completed one Phase 1 trial of the compound. No partnership or licensing arrangement for Lipopolysaccharide has been disclosed.
Lipopolysaccharide is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA.
Lipopolysaccharide has been studied in one completed Phase 1 trial, NCT05884242, titled A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge. The trial enrolled 20 healthy adult volunteers in Belgium, was randomized and controlled, and did not use double blinding.
Yes. Lipopolysaccharide is also known as Lipopolysaccharide (LPS). LPS is the common abbreviation used for the compound in trial listings and scientific literature. Both names refer to the same Johnson & Johnson Phase 1 asset.